Sarah Cannon Research Institute shared a post on LinkedIn:
“We’re excited to announce a strategic collaboration between Sarah Cannon Research Institute’s contract research organization, SCRI Development Innovations, and IQVIA to enhance oncology clinical trials globally.
By combining SCRI’s community-based expertise and Accelero model with IQVIA’s global scale and data capabilities, we can transform clinical trial delivery with sponsors and ultimately bring cutting-edge therapies to patients faster.
Meet us at ASCO 2025 in Chicago to learn more about this exciting collaboration.”